MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case

References

• McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34:981–98.10.1016/j.ncl.2016.06.014
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–96.10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Armstrong TS, Cao Y, Scheurer ME, Vera-Bolanos E, Manning R, Okcu MF, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol. 2009;11:825–32.10.1215/15228517-2008-120
   PubMed Web of Science ®Google Scholar
• Sylvester RK, Steen P, Tate JM, Mehta M, Petrich RJ, Berg A, et al. Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients. Anticancer Drugs. 2011;22:104–110.10.1097/CAD.0b013e3283407e9f
   PubMed Web of Science ®Google Scholar
• St-Coeur PD, Cormier M, LeBlanc VC, Morin PJ, Touaibia M. Effect of O6-substituted guanine analogs on O6-methylguanine DNA-methyltransferase expression and glioblastoma cells viability. Med Chem. 2017;13(1): 28–39.
   Web of Science ®Google Scholar
• Remington M, Chtchetinin J, Ancheta K, Nghiemphu PL, Cloughesy T, Lai A. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro Oncol. 2009;11:22–32.
   PubMed Web of Science ®Google Scholar
• Bugni JM, Han J, Tsai MS, Hunter DJ, Samson LD. Genetic association and functional studies of major polymorphic variants of MGMT. DNA Repair (Amst). 2007;6:1116–26.10.1016/j.dnarep.2007.03.023
   PubMed Web of Science ®Google Scholar
• Wang G, Weiss C, Sheng P, Bresnick E. Retrovirus-mediated transfer of the human O6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem Pharmacol. 1996 May 3;51(9):1221–8.
   PubMed Web of Science ®Google Scholar
• Hazra TK, Roy R, Biswas T, Grabowski DT, Pegg AE, Mitra S. Specific recognition of O6-methylguanine in DNA by active site mutants of human O6-methylguanine-DNA methyltransferase. Biochemistry. 1997 May 13;36(19):5769–76.10.1021/bi963085i
   PubMed Web of Science ®Google Scholar
• Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18(1):204–14.10.1158/1055-9965.EPI-08-0632
   PubMed Web of Science ®Google Scholar
• Pegg AE, Fang Q, Loktionova NA. Human variants of O6-alkylguanine-DNA alkyl transferase. DNA Repair (Amst). 2007;6:1071–8.10.1016/j.dnarep.2007.03.012
   PubMed Web of Science ®Google Scholar
• Shiraishi A, Sakumi K, Sekiguchi M. Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis. 2000;21:1879–83.10.1093/carcin/21.10.1879
   PubMed Web of Science ®Google Scholar
• Wiencke JK, Aldape K, McMillan A, Wiemels J, Moghadassi M, Miike R, et al. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. Cancer Epidemiol Biomarkers Prev. 2005;14:1774–83.10.1158/1055-9965.EPI-05-0089
   PubMed Web of Science ®Google Scholar
• Zawlik I, Vaccarella S, Kita D, Mittelbronn M, Franceschi S, Ohgaki H. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology. 2009;32:21–9.10.1159/000170088
   PubMed Web of Science ®Google Scholar
• Felini MJ, Olshan AF, Schroeder JC, North KE, Carozza SE, Kelsey KT, et al. DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology. 2007;29(1–2):55–8.10.1159/000108919
   PubMed Web of Science ®Google Scholar
• Adel Fahmideh M, Schwartzbaum J, Frumento P, Feychting M. Association between DNA repair gene polymorphisms and risk of glioma: a systematic review and meta-analysis. Neuro Oncol. 2014;16:807–14.10.1093/neuonc/nou003
   PubMed Web of Science ®Google Scholar
• Liu K, Jiang Y. Polymorphisms in DNA repair gene and susceptibility to glioma: a systematic review and meta-analysis based on 33 studies with 15 SNPs in 9 genes. Cell Mol Neurobiol. 2017;37(2):263–274. doi:10.1007/s10571-016-0367-y.
   Web of Science ®Google Scholar
• Huang WY, Olshan AF, Schwartz SM, Berndt SI, Chen C, Llaca V, et al. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:1747–53.10.1158/1055-9965.EPI-05-0162
   PubMed Web of Science ®Google Scholar
• Zhang M, Huang WY, Andreotti G, Gao YT, Rashid A, Chen J, et al. Variants of DNA repair genes and the risk of biliary tract cancers and stones: a population-based study in china. Cancer Epidemiol Biomarkers Prev. 2008;17:2123–7.10.1158/1055-9965.EPI-07-2735
   PubMed Web of Science ®Google Scholar
• Jiao J, Zheng T, Lan Q, Chen Y, Deng Q, Bi X, et al. Occupational solvent exposure, genetic variation of DNA repair genes, and the risk of non-Hodgkin’s lymphoma. Eur J Cancer Prev. 2012;21:580–4.10.1097/CEJ.0b013e328351c762
   PubMed Web of Science ®Google Scholar
• Guo H, Bassig BA, Lan Q, Zhu Y, Zhang Y, Holford TR, et al. Polymorphisms in DNA repair genes, hair dye use, and the risk of non-Hodgkin lymphoma. Cancer Causes Control. 2014;25:1261–70.10.1007/s10552-014-0423-1
   PubMed Web of Science ®Google Scholar
• Dubois J, Etienne G, Laroche-Clary A, Lascaux A, Bidet A, Lippert E, et al. Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms. Eur J Cancer. 2014;50:418–24.10.1016/j.ejca.2013.10.012
   PubMed Web of Science ®Google Scholar